Current Perspectives of Anticoagulation in Patients With COVID-19

J Cardiovasc Pharmacol. 2020 Aug;76(2):146-150. doi: 10.1097/FJC.0000000000000861.

Abstract

Thromboembolism and myocardial injury is common in patients with COVID-19. Low-molecular-weight heparin appears to be associated with a good prognosis in patients with COVID-19 and has the ability to reduce coagulation and inflammation markers. Hospitalized patients with COVID-19 should be placed on thromboprophylaxis with the option of full therapeutic anticoagulation or tissue plasminogen activator in high-risk or mechanically ventilated patients. Thromboprophylaxis should also be considered at hospital discharge for high-risk patients. Clinical judgment should be used to evaluate the bleeding and safety risk of anticoagulation in patients with COVID-19 without confirmed data.

Publication types

  • Review

MeSH terms

  • Anticoagulants / adverse effects
  • Anticoagulants / therapeutic use*
  • Betacoronavirus / pathogenicity*
  • Blood Coagulation / drug effects*
  • COVID-19
  • COVID-19 Drug Treatment
  • Clinical Decision-Making
  • Coronavirus Infections / blood
  • Coronavirus Infections / diagnosis
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / virology
  • Hemorrhage / chemically induced
  • Host-Pathogen Interactions
  • Humans
  • Pandemics
  • Patient Selection
  • Pneumonia, Viral / blood
  • Pneumonia, Viral / diagnosis
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / virology
  • Risk Assessment
  • Risk Factors
  • SARS-CoV-2
  • Thromboembolism / blood
  • Thromboembolism / diagnosis
  • Thromboembolism / prevention & control*
  • Thromboembolism / virology
  • Treatment Outcome

Substances

  • Anticoagulants